KOSPIBiotech & Pharma101140

Inbiogen

₩4,705▼ 0.11%2026-11-18 close
Market Cap
₩47.3B
Turnover
₩3,406,045
Volume
729 shares
Shares out.
10M
PER
—
PBR
0.3×
EPS
-₩3,418
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Narrow, but Earnings Hinge on an Affiliate

Inbiogen's 2025 revenue was KRW 6.3 billion and its operating loss was KRW 4.33 billion, so the operating deficit narrowed, but bottom-line results have depended on equity-method gains from an affiliate and net losses have continued since the fourth quarter of 2025.

  1. 1

    2025 revenue was KRW 6.3 billion, down 10.6% year on year, and the operating loss was KRW 4.33 billion, smaller than the KRW 6.33 billion loss in 2022.

  2. 2

    The operating margin improved from -98.6% in 2023 to -68.8% in 2025 but remains negative.

  3. 3

    Kiosk operations account for roughly 90% of revenue, and reports point to a heavy cost-of-sales burden.

  4. 4

    Net income attributable to controlling shareholders turned positive in 2023, reached KRW 16.1 billion in 2024, and returned to a KRW 1.42 billion net loss in 2025.

  5. 5

    Third-quarter 2026 revenue was KRW 1.0 billion, down 53.5% year on year, and the cumulative net loss attributable to controlling shareholders over the last four quarters is KRW 34.1 billion.

02

Business structure

Inbiogen (101140) runs a kiosk business and a food and beverage (F&B) business. It is classified under the bio and pharmaceutical sector, but its actual operations are far from pharmaceuticals or biotech.

The kiosk business does not manufacture units; it buys finished machines and distributes, rents and leases them, earning money from equipment sales proceeds, lease fees and commissions.

Under this model, the cost of sales is necessarily high, and an IB Tomato report said third-quarter cost of sales reached KRW 5.9 billion, above revenue of KRW 5.6 billion. Kiosks generate most of the revenue: the same report said third-quarter kiosk sales of KRW 5.1 billion accounted for about 90% of total revenue.

Reporting on 2023 revenue of KRW 6.2 billion broke it into KRW 2.4 billion from kiosks and KRW 3.8 billion from F&B. A separate tally puts kiosks at 100% of 2026 second-quarter revenue, so the segment mix appears to depend on the basis of classification.

On the competitive side, the spread of unmanned stores has lifted demand for kiosk installations, while market saturation and a shrinking number of restaurant operators limit growth. In 2024, government support for installing unmanned equipment and the exit of some rivals helped revenue recover somewhat.

A smaller number of restaurant operators narrows the customer base for kiosk installations, which bears directly on demand. Equity-method valuation gains from the affiliate Bident make up a large share of net earnings, and strengthening the core business is cited as a survival task.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.1B-₩1.1B−49.1%
2025Q4₩700M-₩1B−144.3%
2026Q1₩800M-₩1B−124.6%
2026Q2₩1.5B-₩900M−61.2%
2026Q3₩1B-₩800M−76.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩11.4B-₩6.3B-₩117.2B−55.5%−109.7%35.0%
2023₩6.2B-₩6.2B₩11.3B−98.6%7.9%1.8%
2024₩7B-₩6.1B₩16.1B−86.5%10.1%1.8%
2025₩6.3B-₩4.3B-₩1.4B−68.8%−0.9%1.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 11.4 billion in 2022 to KRW 6.24 billion in 2023, down 45.3% year on year. It recovered to KRW 7.04 billion in 2024, up 12.8%, before falling to KRW 6.3 billion in 2025, down 10.6%. Among 2022 to 2025, 2022 was the largest year and 2023 the smallest.

The operating loss was KRW 6.33 billion in 2022, KRW 6.15 billion in 2023, KRW 6.09 billion in 2024 and KRW 4.33 billion in 2025, and the deficit continued each year while the loss narrowed. The company has posted operating losses for four consecutive years from 2022 through 2025.

The operating margin worsened from -55.5% in 2022 to -98.6% in 2023 and then improved to -86.5% in 2024 and -68.8% in 2025. The 2023 deterioration reflects a 45.3% drop in revenue. Net results moved in a different direction from operating results.

The net loss attributable to controlling shareholders of KRW 117.2 billion in 2022 turned into a net profit of KRW 1.13 billion in 2023, rose to KRW 1.61 billion in 2024 (up 42.1%), and returned to a net loss of KRW 1.42 billion in 2025.

According to an IB Tomato report, equity-method gains were KRW 41.1 billion in 2023 and KRW 21.5 billion in 2024, so affiliate income offset the operating losses. The 2025 net loss of KRW 1.42 billion was smaller than the operating loss of KRW 4.33 billion, which suggests non-operating items partly offset it.

At the end of 2025, total equity was KRW 157.6 billion, all of it attributable to controlling shareholders, total liabilities were KRW 2.35 billion, and the debt ratio was 1.5%.

Operating cash flow was negative in every year: KRW -11.5 billion in 2022, KRW -1.05 billion in 2023, KRW -33.13 million in 2024 and KRW -5.55 billion in 2025.

Quarterly revenue went from KRW 2.15 billion in the third quarter of 2025 to KRW 661 million in the fourth quarter (down 69.2% from the prior quarter), then KRW 786 million in the first quarter of 2026, KRW 1.51 billion in the second quarter (up 92.0%) and KRW 998 million in the third quarter (down 33.9% from the prior quarter and down 53.5% year on year).

The operating loss has been reported in each of the last five quarters, from KRW 1.05 billion in the third quarter of 2025 to KRW 766 million in the third quarter of 2026, and the third-quarter loss narrowed from a year earlier.

Net results attributable to controlling shareholders went from a KRW 8.17 billion profit in the third quarter of 2025 to a KRW 12.7 billion loss in the fourth quarter, widened to KRW 14.7 billion in the first quarter of 2026, narrowed to KRW 1.48 billion in the second quarter and widened again to KRW 5.24 billion in the third quarter.

Quarterly net results swing far more than operating results, which points to a large influence from non-operating items.

05

Industry analysis

The spread of unmanned stores is lifting demand for kiosks. According to FnGuide, standalone revenue for the first three quarters of 2025 rose 15.6% year on year, and the operating loss fell 15.3%.

The same source noted that the number of installed and operating kiosks increased but that gross profit declined because of cost pressure. Rising demand therefore does not translate directly into better profitability.

Reports have repeatedly pointed out that a model of buying finished machines and distributing them carries a higher cost-of-sales ratio than a business that manufactures its own equipment. Government support for installing unmanned equipment was cited as a factor behind the 2024 revenue recovery.

Market saturation and a shrinking number of restaurant operators, on the other hand, are cited as factors narrowing the base of kiosk buyers. The exit of some rivals gave short-term benefits, but whether the market itself keeps growing depends on whether installation demand continues.

Although the company is classified under bio and pharmaceuticals, its business model is closer to kiosk distribution and rental plus restaurant F&B, so the cycle that matters is restaurant installation demand and the durability of unmanned-store policy, not clinical or approval timelines in biotech. How long the policy support lasts is the key variable for demand.

06

Outlook

The starting point for the outlook is the 2026 quarterly trend. Revenue was KRW 786 million in the first quarter of 2026, KRW 1.51 billion in the second quarter and KRW 998 million in the third quarter, with large swings from quarter to quarter.

The operating loss narrowed from KRW 980 million in the first quarter to KRW 766 million in the third quarter, but the net loss attributable to controlling shareholders widened to KRW 5.24 billion in the third quarter, so non-operating items are driving bottom-line volatility.

An IB Tomato report projected that the outcome of the listing-eligibility review at the affiliate Bident would have a decisive effect on Inbiogen's liquidity and credibility; this is a view from the time of publication, and filings reflecting the review outcome are the items to track.

Company-announced orders, capacity expansion or new product schedules were not part of the sources used here, so they are not treated as a basis for this outlook. In kiosks, the key question for revenue recovery is how far policy support for unmanned stores turns into installation demand.

The benefit from rivals exiting the market was largely one-off in nature, so the quarterly revenue trend needs to show whether the revenue structure itself has changed. The F&B share appears differently depending on the basis of classification, so the segment note in the annual report is the reference.

In the 2026 annual report, the next regular filing, the full-year operating margin and equity-method results are the checkpoints. The fourth-quarter 2026 result will show whether the operating loss extends to a sixth consecutive quarter.

07

Valuation

PER
—
PBR
0.3×
ROE
-22.2%
EPS
-₩3,418
BPS
₩13,630
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the company has posted net losses over the last four quarters. The price-to-book ratio is below 1x, meaning the share price is trading below book value.

Total equity of KRW 157.6 billion at the end of 2025 is entirely attributable to controlling shareholders, and liabilities of KRW 2.35 billion keep the debt burden small.

Valuation readings are highly sensitive to equity-method gains and losses from the affiliate, so the operating result and the equity-method result need to be read together. Dividends have not been paid, so there is no dividend-based shareholder return.

Paid-in capital was reduced from KRW 70.4 billion in 2022 to KRW 5 billion in 2023, which changed the capital base itself. While losses continue, earnings-based comparisons are difficult, and reading net asset value alongside the operating trend is the more practical approach.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Signs of Kiosk Demand Growth

Growing unmanned-store adoption shows up in standalone results for the first three quarters of 2025, when revenue rose 15.6% and the operating loss fell 15.3%. In 2024, government support for installing unmanned equipment and the exit of some rivals were reflected in the revenue recovery. Kiosk demand is the main factor supporting the core revenue base.

Narrowing Operating Losses

The operating loss narrowed from KRW 6.33 billion in 2022 to KRW 4.33 billion in 2025, and the operating margin improved from -98.6% in 2023 to -68.8% in 2025. The KRW 766 million operating loss in the third quarter of 2026 was smaller than the KRW 1.05 billion in the third quarter of 2025.

The narrowing loss reflects a gradual improvement in the core cost structure, and whether this continues is the next item to track.

Equity Base and Light Debt

At the end of 2025, total equity was KRW 157.6 billion against total liabilities of KRW 2.35 billion, a debt ratio of 1.5%. The debt ratio fell from 35.0% in 2022 to the 1% range from 2023 onward. The change followed a capital reduction and a restructuring of the balance sheet. A light debt load is cited as a factor that helps the company absorb operating losses.

09

Bear factors

Five Straight Quarters of Operating Losses

The operating loss has continued for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026. The cumulative net loss attributable to controlling shareholders over the last four quarters is KRW 34.1 billion. Third-quarter 2026 revenue of KRW 1.0 billion fell 53.5% year on year. Revenue decline combined with continued losses is the main bearish factor.

Limits of the Kiosk Cost Structure

According to an IB Tomato report, third-quarter cost of sales exceeded revenue, and the finished-machine purchase model carries a high cost-of-sales ratio. Kiosks account for about 90% of revenue, so the business is concentrated in one product line.

Market saturation and a shrinking number of restaurant operators are cited as narrowing the buyer base. Under this structure, a revenue decline can easily widen losses.

Dependence on an Affiliate and Listing Review

Equity-method gains of KRW 41.1 billion in 2023 and KRW 21.5 billion in 2024 were the main factor offsetting core operating losses. Reports said the listing-eligibility review at the affiliate Bident could affect Inbiogen's liquidity and credibility.

The company received disclaimers of opinion from its external auditor for 2022 and 2023, which led to a trading halt. Financing cash flow turned negative from 2023, and cash outflows have continued.

10

Risk factors

Audit and Disclosure Credibility

The company received disclaimers of opinion from its external auditor in both 2022 and 2023, which led to a trading halt, and trading resumed after an amended annual report. Reports said the share price fell 30% after trading resumed.

Whether credibility has been restored should be checked against future audit opinions and any further corrections. A change in audit opinion could again affect trading conditions.

Affiliate Dependence and Liquidity

Operating and net results have moved in different directions, and net income has depended heavily on equity-method results from the affiliate. Operating cash flow was KRW -5.55 billion in 2025, and financing cash flow has been negative since 2023.

The outcome of the listing review at the affiliate could affect liquidity assessments. The pace of core-business improvement will determine how much this dependence can be reduced.

Business Concentration and Cost Structure

Kiosks account for about 90% of revenue, so the business is concentrated in one product line. Reports that cost of sales exceeded revenue point to a heavy cost burden. Third-quarter 2026 revenue fell 53.5% year on year. If market saturation and fewer restaurant operators persist, the room for revenue recovery could stay limited.

11

What to watch next

  1. Around late January 2027 (typical timing)

    Preliminary fourth-quarter 2026 results. Check whether the operating loss extends to a sixth straight quarter and whether net results attributable to controlling shareholders move out of the four-quarter loss streak.

  2. By March 31, 2027

    Filing deadline for the 2026 annual report. This is the first regular filing that confirms full-year results, the operating margin, equity-method results and the segment revenue note.

  3. By May 15, 2027

    Filing deadline for the first-quarter 2027 quarterly report. Check whether kiosk revenue recovers on a quarterly basis and whether the narrowing operating loss continues.

12

Overall view

Inbiogen runs kiosk distribution and rental and an F&B business, and its operations differ from its bio and pharmaceutical sector classification. Revenue was KRW 6.3 billion in 2025 and the operating loss was KRW 4.33 billion, and the operating loss has narrowed since 2022.

However, the company has posted operating losses for four consecutive years, and operating losses have continued for five straight quarters through the third quarter of 2026.

Net results attributable to controlling shareholders were positive in 2023 and 2024 but depended heavily on equity-method gains from the affiliate, and net losses have continued for four quarters since 2025. Kiosks account for about 90% of revenue, and a heavy cost-of-sales burden is evident.

Total equity of KRW 157.6 billion and a 1.5% debt ratio are the basis of the financial capacity. The listing-review outcome at the affiliate Bident, along with the full-year operating margin and equity-method results in the 2026 annual report, are the next checkpoints.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. investing.com
  2. finance.finup.co.kr
  3. markets.hankyung.com
  4. butler.works
  5. englishdart.fss.or.kr
  6. google.com
  7. daramtickers.com
  8. ibtomato.com
  9. jobkorea.co.kr
  10. comp.fnguide.com
  11. k5.co.kr
  12. catch.co.kr
  13. news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis